-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Hormone-Sensitive Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemiplimab in Hormone-Sensitive Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Hormone-Sensitive Prostate Cancer Drug Details: Cemiplimab (Libtayo) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venetoclax in Transformed Mycosis Fungoides
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Transformed Mycosis Fungoides report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in Transformed Mycosis Fungoides Drug Details: Venetoclax (ABT-199, GDC-0199/RG7601,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ustekinumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ustekinumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARD-501 in Autism Spectrum Disorder (ASD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARD-501 in Autism Spectrum Disorder (ASD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ARD-501 in Autism Spectrum Disorder (ASD) Drug Details: ARD-501 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Gastric Cancer Drug Details: ERAS-601 is under development for the...
-
Product Insights
NewOveractive Bladder – Drugs In Development, 2024
Empower your strategies with our Overactive Bladder – Drugs In Development, 2024 report and make more profitable business decisions. Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feeling a sudden urge to urinate that's difficult to control, experiencing urge incontinence, and awakening two or more times in the night to urinate. Treatment includes...
-
Product Insights
NewPrader-Willi Syndrome (PWS) – Drugs In Development, 2024
Empower your strategies with our Prader-Willi Syndrome (PWS) – Drugs In Development, 2024 report and make more profitable business decisions. Prader-Willi syndrome (PWS) is a rare congenital genetic disorder that results in a number of physical, mental, and behavioral problems. PWS is due to the lack of several genes on one of an individual’s two chromosome 15s. In the majority of cases, there is a deletion. In the remaining cases, the entire chromosome from the father is missing and there are...
-
Product Insights
NewAutism Spectrum Disorder (ASD) – Drugs In Development, 2024
Empower your strategies with our Autism Spectrum Disorder (ASD) – Drugs In Development, 2024 report and make more profitable business decisions. Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. Symptoms range from mild to severe, forming a spectrum. Individuals with ASD may have difficulties in understanding social cues, expressing emotions, and engaging in reciprocal conversations. Sensory sensitivities are common, affecting responses to stimuli. Early intervention and tailored support can enhance communication...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYT-200 in Urethral Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LYT-200 in Urethral Cancer Drug Details: LYT-200 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADT-101 in Substance (Drug) Abuse
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ADT-101 in Substance (Drug) Abuse report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADT-101 in Substance (Drug) Abuse Drug Details: ADT-101 is under development...